RayKnowChina Research Map
Shortlist

China Medical University (Shenyang)

中国医科大学

ShenyangUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.5%Leads under 1 in 100 of China's research papers on NPC

Led 11 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
11
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 442025
ThemesRadiotherapy techniqueImmunotherapyImaging & AI

Hospitals counted here

  1. Shengjing Hospital of China Medical University5
  2. First Hospital of China Medical University5
  3. Fourth Affiliated Hospital of China Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.7%Leads under 1 in 100 of China's research papers on ESCC

Led 20 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
0
Research papers it led
20
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 2220212022: 0020222023: 2220232024: 0020242025: 112025
ThemesRadiotherapyMolecular markers & genomicsNeoadjuvant & combined treatment

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Liaoning Cancer Hospital & Institute9
  2. First Hospital of China Medical University7
  3. Fourth Affiliated Hospital of China Medical University Counted in the group total1
  4. China Medical University Hsinchu Hospital1
  5. Shengjing Hospital of China Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Correlation of nutritional support and immunonutritional indicators with prognosis and survival in esophageal squamous cell carcinoma patients undergoing concurrent chemoradiotherapy.2025Nutrition journalFree full text
  2. Mucosal esophageal carcinoma following endoscopic submucosal dissection with giant gastric metastasis: A case report and review of literature.2023World journal of gastroenterologyFree full text
  3. PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis.2023BMC cancerFree full text
  4. Identification of DNA-Repair-Related Five-Gene Signature to Predict Prognosis in Patients with Esophageal Cancer.2021Pathology oncology research : PORFree full text
  5. circRNA_141539 can serve as an oncogenic factor in esophageal squamous cell carcinoma by sponging miR-4469 and activating CDK3 gene.2021AgingFree full text
Trials on ClinicalTrials.gov6
  1. Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCCRecruitingNCT07733830Study sitePhase 2Start 2026-07
  2. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  3. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  4. Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCCRecruitingNCT06637163Study sitePhase 2Start 2024-10
  5. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedNCT05461794Study sitePhase 2Start 2022-10
  6. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
1.0%Leads about 1 in 98 of China's research papers on HCC

Led 151 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
3
Research papers it led
151
Trials it led
9
Share of China's trials
0.6%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs

Hospitals counted here

  1. First Hospital of China Medical University61
  2. Shengjing Hospital of China Medical University60
  3. Liaoning Cancer Hospital & Institute16
  4. Fourth Affiliated Hospital of China Medical University11
  5. China Medical University Hospital1
  6. Aviation General Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.2024Lancet (London, England)
  2. Tumor stiffness as an imaging biomarker of tyrosine kinase inhibitor response: A preclinical study.2026Magnetic resonance imaging
  3. Identifying Low-Risk Patients with Cirrhosis and Acute Gastrointestinal Bleeding That May Not Require Urgent Endoscopy.2026Advances in therapyFree full text
  4. Non-Gaussian diffusion MRI models for preoperative assessment of microvascular invasion in hepatocellular carcinoma.2026Abdominal radiology (New York)
  5. Predicting the outcome of transarterial chemoembolization combined with targeted immunotherapy for unresectable hepatocellular carcinoma based on MRI radiomics.2025Scientific reportsFree full text
Trials on ClinicalTrials.gov6
  1. Pragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CTNot yet recruitingNCT07768085Lead sponsorN/AStart 2026-08
  2. Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor ThrombusRecruitingNCT07483359Lead sponsorPhase 2Start 2026-05
  3. Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and DiabetesNot yet recruitingNCT07557914Lead sponsorPhase 2Start 2026-10
  4. First in Human Study of SIM0610 in Solid TumorsRecruitingNCT07348211Study sitePhase 1Start 2026-01
  5. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCCRecruitingNCT07547553Study sitePhase 1/Phase 2Start 2026-05
  6. Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular CarcinamoRecruitingNCT07239245Study sitePhase 2Start 2025-11

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
2.0%Leads about 1 in 50 of China's research papers on Stomach cancer ▼ from 3.9%

Led 198 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
2
Research papers it led
198
Trials it led
14
Share of China's trials
1.0%
Share of the world's papers
0.9%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 332025
ThemesPeritoneal spread & advanced diseaseImaging & AIImmunotherapy & targeted drugs

Hospitals counted here

  1. First Hospital of China Medical University109
  2. Liaoning Cancer Hospital & Institute40
  3. Shengjing Hospital of China Medical University27
  4. Fourth Affiliated Hospital of China Medical University20
  5. Dalian Municipal Central Hospital Counted in the group total1
  6. Dandong Central Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. HDAC3-dependent transcriptional repression of FOXA2 regulates FTO/m6A/MYC signaling to contribute to the development of gastric cancer.2021Cancer gene therapyRCT
  2. Multicenter research: tumor microenvironment features combined with tumor cell characteristics predict lymph node metastasis in early gastric cancer.2026Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  3. Case report: Spatiotemporal HER2 heterogeneity in AFP-producing gastric cancer: navigating long-term survival with molecularly-guided therapy in a refractory case.2025Frontiers in immunologyFree full text
  4. Frailty as a predictor of postoperative outcomes in older gastroesophageal cancer patients: a systematic review and meta-analysis.2025BMC geriatricsFree full text
  5. Fruquintinib and sintilimab plus SOX as perioperative therapy for locally resectable advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase II clinical trial.2025Frontiers in immunologyFree full text
Trials on ClinicalTrials.gov6
  1. Two-component Radiology-guided Autonomous Cascade Engine (TRACE)RecruitingNCT07651644Lead sponsorN/AStart 2026-06
  2. SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal CancerNot yet recruitingNCT06666166Lead sponsorPhase 2Start 2024-12
  3. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  4. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Study sitePhase 3Start 2025-02
  5. Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive TumorsRecruitingNCT06940102Study siteStart 2025-03
  6. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
0.7%Leads under 1 in 100 of China's research papers on Retinoblastoma New since 2021

Led 2 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Shengjing Hospital of China Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Chordoma

脊索瘤
0.0%Leads none of China's research papers on Chordoma

Led 0 of 105 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.8%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
2.1%Leads about 1 in 47 of China's research papers on Osteosarcoma ▼ from 2.8%

Led 48 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
48
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 0020242025: 112025

Over half of these papers are lab or animal studies.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
2.9%Leads about 1 in 35 of China's research papers on Gastrointestinal stromal tumour

Led 15 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
15
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 0020242025: 112025

Hospitals counted here

  1. First Hospital of China Medical University6
  2. Shengjing Hospital of China Medical University6
  3. Liaoning Cancer Hospital & Institute2
  4. Affiliated Hospital of China Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
1.2%Leads about 1 in 81 of China's research papers on Neuroblastoma

Led 14 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
14
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 332025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Shengjing Hospital of China Medical University10
  2. Fourth Affiliated Hospital of China Medical University2
  3. First Hospital of China Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Ewing sarcoma

尤文肉瘤
1.2%Leads about 1 in 81 of China's research papers on Ewing sarcoma

Led 2 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. First Hospital of China Medical University1
  2. Shengjing Hospital of China Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
0.7%Leads under 1 in 100 of China's research papers on Myeloma ▼ from 2.0%

Led 12 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
0
Research papers it led
12
Trials it led
2
Share of China's trials
0.4%
Share of the world's papers
0.1%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 2220242025: 112025
ThemesDrug combinationsBispecific & antibody drugsRelapse & resistance

Hospitals counted here

  1. Shengjing Hospital of China Medical University7
  2. First Hospital of China Medical University4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.2024The New England journal of medicineRCT
  2. Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis.2025Frontiers in immunologyFree full text
  3. Megalosplenia as an initial manifestation of multiple myeloma with a novel CYLD gene mutation: A case report and literature review.2024MedicineFree full text
  4. Coexistence of plasma cell neoplasia and myelodysplastic syndrome with excess blasts: case reports and literature review.2021Annals of palliative medicine
  5. Plasmablastic myeloma/leukemia variant of monomorphic posttransplant lymphoproliferative disorder.2021Blood
Trials on ClinicalTrials.gov6
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  2. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  3. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple MyelomaRecruitingNCT06049290Study sitePhase 1/Phase 2Start 2023-10
  4. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationRecruitingNCT05243797Study sitePhase 3Start 2022-09
  5. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  6. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Study sitePhase 1/Phase 2Start 2021-09

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
0.9%Leads under 1 in 100 of China's research papers on B-ALL New since 2021

Led 2 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 0020242025: 002025
ThemesPhiladelphia chromosome & genetics

Hospitals counted here

  1. Shengjing Hospital of China Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
0.2%Leads under 1 in 100 of China's research papers on Aplastic anaemia ▼ from 1.2%

Led 1 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.06%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025
ThemesClonal evolution & PNH

Hospitals counted here

  1. Shengjing Hospital of China Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led1
  1. Early differential diagnosis of pancytopenia related diseases based on serum surface-enhanced Raman spectroscopy.2024Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
0.5%Leads under 1 in 100 of China's research papers on HLH

Led 2 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025
ThemesEBV & infection triggersGenetics & inherited formsDiagnosis & prognosis

Hospitals counted here

  1. First Hospital of China Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
0.7%Leads under 1 in 100 of China's research papers on Haemophilia A New since 2021

Led 2 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.07%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. First Hospital of China Medical University1
  2. People's Hospital, China Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led2
  1. Effect of different incubation times on the detection of factor VIII inhibitor in acquired hemophilia A.2022Clinical chemistry and laboratory medicine
  2. Mechanisms of Bone Remodeling Disorder in Hemophilia.2021Seminars in thrombosis and hemostasis
Trials on ClinicalTrials.gov1
  1. Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with InhibitorCompletedNCT06289166Study sitePhase 2Start 2024-03

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
1.7%Leads about 1 in 61 of China's research papers on NMOSD ▲ from 0.7%

Led 8 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 222025
ThemesAntibodies & diagnosisRelapse preventionAcute attack treatment

Hospitals counted here

  1. First Hospital of China Medical University6
  2. Shengjing Hospital of China Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgG4-related disease

IgG4相关性疾病
3.7%Leads about 1 in 27 of China's research papers on IgG4-RD ▲ from 2.0%

Led 9 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.1%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 002025
ThemesTreatment & relapseKidney, retroperitoneum & vesselsDiagnosis & look-alikes

Hospitals counted here

  1. First Hospital of China Medical University6
  2. Shengjing Hospital of China Medical University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
2.6%Leads about 1 in 38 of China's research papers on Myasthenia gravis ▲ from 0.8%

Led 13 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
0
Research papers it led
13
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 332025
ThemesAntibodies & diagnosisBiologic & complement drugsThymus & thymectomy

Hospitals counted here

  1. First Hospital of China Medical University9
  2. Shengjing Hospital of China Medical University4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Wilson disease

肝豆状核变性(Wilson 病)
1.5%Leads about 1 in 67 of China's research papers on Wilson disease

Led 3 of 201 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.5%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 002025
ThemesGenetics (ATP7B)Diagnosis & copper testsChildren

Hospitals counted here

  1. Shengjing Hospital of China Medical University2
  2. First Hospital of China Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Biliary atresia

胆道闭锁
1.9%Leads about 1 in 53 of China's research papers on Biliary atresia ▲ from 0.8%

Led 4 of 214 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.8%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 1120242025: 002025
ThemesScreening & diagnosisDisease mechanisms

Hospitals counted here

  1. Shengjing Hospital of China Medical University4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
0.8%Leads under 1 in 100 of China's research papers on Anti-NMDA receptor encephalitis New since 2021

Led 2 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

Hospitals counted here

  1. First Hospital of China Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Takayasu arteritis

大动脉炎
0.5%Leads under 1 in 100 of China's research papers on Takayasu arteritis

Led 1 of 187 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (24.6%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Shengjing Hospital of China Medical University1
  2. Liaoning Cancer Hospital & Institute1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led1
  1. A new predictor of disease activity in Takayasu's arteritis patients: pericarotid fat density.2025BMC medical imaging
Trials on ClinicalTrials.gov3
  1. Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's ArteritisNot yet recruitingNCT07451665Study sitePhase 4Start 2026-04
  2. A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)Active, not recruitingNCT04161898Study sitePhase 3Start 2020-02
  3. Takayasu Arteritis Clinical Trial in ChinaCompletedNCT02981979Study siteN/AStart 2016-12

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.9%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis

Led 9 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 2220242025: 222025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Shengjing Hospital of China Medical University5
  2. Fourth Affiliated Hospital of China Medical University3
  3. First Hospital of China Medical University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. SCARF2 is a target for chronic obstructive pulmonary disease: Evidence from multi-omics research and cohort validation.2024Aging cell
  2. Peripheral blood leucocyte telomere length is associated with progression of interstitial lung disease in systemic sclerosis.2021Thorax
  3. Ubiquitin-specific peptidase 10 attenuates bleomycin-induced pulmonary fibrosis via modulating autophagy depending on sirtuin 6-mediated AKT/mTOR.2025Cell biology and toxicology
  4. PLAC8 attenuates pulmonary fibrosis and inhibits apoptosis of alveolar epithelial cells via facilitating autophagy.2025Communications biology
  5. The involvement of HDAC3 in the pathogenesis of lung injury and pulmonary fibrosis.2024Frontiers in immunology
Trials on ClinicalTrials.gov6
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary FibrosisTerminatedNCT06097260Study sitePhase 2Start 2023-11
  3. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05938920Study sitePhase 2Start 2023-06
  4. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03
  5. A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04594707Study sitePhase 3Start 2021-08
  6. Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT04419558Study sitePhase 3Start 2020-09

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
0.6%Leads under 1 in 100 of China's research papers on Amyotrophic lateral sclerosis

Led 5 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.08%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 112025

Hospitals counted here

  1. First Hospital of China Medical University3
  2. Shengjing Hospital of China Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
1.4%Leads about 1 in 71 of China's research papers on Duchenne muscular dystrophy ▼ from 2.0%

Led 3 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Shengjing Hospital of China Medical University1
  2. First Hospital of China Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Behçet disease

白塞病
0.8%Leads under 1 in 100 of China's research papers on Behçet disease New since 2021

Led 2 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.9%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Shengjing Hospital of China Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
1.1%Leads about 1 in 92 of China's research papers on IgA nephropathy ▼ from 1.9%

Led 8 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 1120242025: 112025

Hospitals counted here

  1. Shengjing Hospital of China Medical University4
  2. First Hospital of China Medical University4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteogenesis imperfecta

成骨不全症
2.0%Leads about 1 in 50 of China's research papers on Osteogenesis imperfecta New since 2021

Led 2 of 99 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Shengjing Hospital of China Medical University1
  2. First Hospital of China Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
0.3%Leads under 1 in 100 of China's research papers on Primary biliary cholangitis ▼ from 1.3%

Led 1 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. First Hospital of China Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary sclerosing cholangitis

原发性硬化性胆管炎
3.0%Leads about 1 in 33 of China's research papers on Primary sclerosing cholangitis ▲ from 2.0%

Led 3 of 100 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.0%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. First Hospital of China Medical University2
  2. Shengjing Hospital of China Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Congenital diaphragmatic hernia

先天性膈疝
0.0%Leads none of China's research papers on Congenital diaphragmatic hernia

Led 0 of 60 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (18.3%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov

Hirschsprung disease

先天性巨结肠
0.0%Leads none of China's research papers on Hirschsprung disease

Led 0 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.0%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症
3.6%Leads about 1 in 28 of China's research papers on Inherited epidermolysis bullosa ▼ from 7.1%

Led 2 of 56 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.5%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. First Hospital of China Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov